ML385: Selective NRF2 Inhibitor for Cancer and Oxidative Stress Research

Executive Summary: ML385 (SKU B8300, APExBIO) is a small molecule inhibitor of NRF2, with an IC₅₀ of 1.9 μM. It suppresses NRF2-dependent gene expression in a dose- and time-dependent manner, validated in A549 non-small cell lung cancer (NSCLC) cell lines. ML385 demonstrates reduction of tumor growth and metastasis in vivo, especially when combined with chemotherapeutics such as carboplatin. The compound is insoluble in ethanol and water but dissolves at ≥13.33 mg/mL in DMSO. Storage at −20°C and avoidance of long-term solution storage are recommended for stability (APExBIO).

Biological Rationale

Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor regulating genes involved in antioxidant responses, detoxification, and cellular defense against oxidative stress. NRF2 activation confers resistance to chemotherapeutics and promotes survival in cancer cells, notably in NSCLC (Zhou et al., 2024). Overactivation of NRF2 is linked to poor prognosis, drug resistance, and increased metastasis in several cancer types. In addition, NRF2 modulates genes essential for NADPH production and iron metabolism, with relevance in ferroptosis and liver injury models. Targeting NRF2 with selective inhibitors such as ML385 is critical for dissecting these pathways and developing novel therapeutic interventions (CalpainInhibitorII overview).

Mechanism of Action of ML385

ML385 (CAS 846557-71-9) is a first-in-class, selective small molecule that inhibits NRF2 by preventing its binding to DNA and subsequent transcriptional activation (APExBIO). Specifically, ML385 binds to the Neh1 domain of NRF2, disrupting heterodimerization with small Maf proteins. This inhibition reduces the expression of NRF2 target genes, including those involved in glutathione metabolism, heme oxygenase-1 (HO-1), and NADPH-regenerating enzymes. In both in vitro and in vivo systems, ML385 produces a measurable, dose-dependent decrease in NRF2 pathway activity. This selectivity distinguishes ML385 from broader antioxidants or general transcriptional inhibitors.

Evidence & Benchmarks

• ML385 exhibits an IC₅₀ of 1.9 μM for NRF2 inhibition in A549 NSCLC cells (APExBIO).
• ML385 administration (100 mg/kg/day, i.p.) reduces NRF2 signaling and downstream gene expression in rat models of alcoholic liver disease (Zhou et al., 2024).
• In NSCLC mouse models, ML385 decreases tumor growth and metastasis, with enhanced efficacy when combined with carboplatin (CalpainInhibitorII overview).
• ML385 is insoluble in ethanol and water but achieves ≥13.33 mg/mL solubility in DMSO, supporting high-concentration stock preparation (APExBIO).
• Cellular assays show time- and dose-dependent downregulation of NRF2 target genes (e.g., NQO1, HO-1) in the presence of ML385 (Zhou et al., 2024).
• PCP-induced upregulation of NRF2 signaling is reversed by ML385 cotreatment in both cell and animal models, demonstrating pathway specificity (Zhou et al., 2024).

This article clarifies and updates prior reviews such as Leveraging Selective NRF2 Inhibition with ML385 by focusing on atomic, benchmarked data and recent in vivo findings.

Applications, Limits & Misconceptions

ML385 is primarily used in cancer research to investigate NRF2 signaling, therapeutic resistance, and oxidative stress modulation. It is a preferred tool for studies in NSCLC, hepatocellular carcinoma, and ferroptosis. ML385 enables mechanistic dissection of NRF2’s role in drug resistance and cell survival. It also supports combinatorial strategies with chemotherapeutics, such as carboplatin, to test for synthetic lethality or resistance reversal.

For broader mechanistic context, see ML385 and NRF2 Inhibitors: Unveiling New Paradigms in Cancer and Ferroptosis, which provides translational insight, whereas this article emphasizes atomic claims and experimental parameters.

Common Pitfalls or Misconceptions

• ML385 is not suitable for studies requiring NRF2 activation; it is an inhibitor only.
• ML385 is insoluble in water and ethanol—use only DMSO for stock solutions.
• Long-term storage of ML385 in solution can lead to degradation; always prepare fresh aliquots.
• Non-selective effects may arise at concentrations >10 μM; titration is required to maintain specificity.
• ML385’s efficacy is context-dependent and may vary with cell type, gene expression background, and combination partners.

Workflow Integration & Parameters

ML385 is typically supplied as a lyophilized solid, stored at −20°C. For experimental use, dissolve ML385 in DMSO to a stock concentration of ≥13.33 mg/mL. Aliquot stocks to minimize freeze-thaw cycles. For in vitro assays, standard working concentrations range from 0.5–5 μM. In animal models, ML385 is administered intraperitoneally at 100 mg/kg/day, as validated in rat models of liver disease and mouse models of NSCLC (Zhou et al., 2024). Avoid use in aqueous buffers or ethanol-based media. Monitor NRF2 target gene expression (e.g., NQO1, HO-1, GCLC) to validate inhibitory activity. For combinatorial studies, ML385 can be co-administered with chemotherapeutics such as carboplatin to probe resistance mechanisms (ML385 Scenario-Driven Solutions).

Compared to previous summaries (ML385: Unveiling New Frontiers), this article provides a workflow-centered, evidence-rich protocol orientation.

Conclusion & Outlook

ML385 (SKU B8300, APExBIO) is a validated, selective NRF2 inhibitor supporting research in cancer biology, drug resistance, and redox biology. Its well-characterized mechanism and benchmarked protocols enable reproducible experiments across in vitro and in vivo models. Ongoing research will likely expand ML385’s applications to additional disease contexts where NRF2 plays a pathogenic role, including metabolic and inflammatory diseases.